Patents Assigned to Immunex Corp.
  • Polynucleotide encoding IL-1 zeta polypeptide
    Patent number: 7033783
    Abstract: The invention is directed to novel, purified and isolated IL-1 zeta and Xrec2 polypeptides and fragments thereof, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and uses thereof.
    Type: Grant
    Filed: June 6, 2001
    Date of Patent: April 25, 2006
    Assignee: Immunex Corp.
    Inventors: John E. Sims, Dirk E. Smith, Teresa L. Born
  • FLK-1 binding proteins
    Patent number: 6994989
    Abstract: A protein designated flk-1bp binds the vascular endothelial cell surface receptor flk-1. Isolated DNA encoding flk-1bp is provided, along with expression vectors and transformed host cells useful in producing flk-1bp polypeptides. Antibodies that are immunoreactive with flk-1bp are generated using the polypeptides disclosed herein.
    Type: Grant
    Filed: November 5, 1996
    Date of Patent: February 7, 2006
    Assignee: Immunex Corp.
    Inventor: Stewart D. Lyman
  • Viral proteins capable of binding LAR
    Patent number: 6852486
    Abstract: A poxvirus protein designated A41L binds to leukocyte common-antigen-related protein (LAR). A41L is a secreted protein that can be purified from the culture supernatant of cells infected with certain poxviruses, or produced using recombinant DNA techniques. A41L polypeptides and LAR polypeptides, and nucleic acids encoding them, are provided herein. Also provided are methods of using such polypeptides and nucleic acids.
    Type: Grant
    Filed: July 3, 2002
    Date of Patent: February 8, 2005
    Assignee: Immunex Corp.
    Inventors: Craig A. Smith, Raymond G. Goodwin
  • Il-1 eta DNA and polypeptides
    Publication number: 20040210038
    Abstract: The invention is directed to novel, purified and isolated IL-1 eta polypeptides and fragments thereof, the polynucleotides encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, peptides derived from these polypeptides, and uses thereof.
    Type: Application
    Filed: May 10, 2004
    Publication date: October 21, 2004
    Applicant: Immunex Corp.
    Inventors: John E. Sims, Blair R. Renshaw
  • IL-1 eta DNA and polypeptides
    Publication number: 20040203116
    Abstract: The invention is directed to novel, purified and isolated IL-1 eta polypeptides and fragments thereof, the polynucleotides encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, peptides derived from these polypeptides, and uses thereof.
    Type: Application
    Filed: May 10, 2004
    Publication date: October 14, 2004
    Applicant: Immunex Corp.
    Inventors: John E. Sims, Blair R. Renshaw
  • Metalloprotease-disintegrin ADAM23 (SVPH3-17) nucleic acids
    Patent number: 6787644
    Abstract: The invention is directed to purified and isolated novel SVPH3-13 or SVPH3-17 polypeptides, the nucleic acids encoding such polypeptides, for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.
    Type: Grant
    Filed: August 7, 2000
    Date of Patent: September 7, 2004
    Assignee: Immunex Corp.
    Inventor: Douglas P. Cerretti
  • Molecules designated B7L-1
    Patent number: 6512095
    Abstract: The invention is directed to B7L-1 as a purified and isolated protein, the DNA encoding the B7L-1, host cells transfected with cDNAs encoding B7L-1 and processes for preparing B7L-1 polypeptides.
    Type: Grant
    Filed: February 6, 2001
    Date of Patent: January 28, 2003
    Assignee: Immunex Corp.
    Inventor: Peter R. Baum
  • Method of stimulating an immune response with activated dendritic cells
    Patent number: 6497876
    Abstract: Antigen-expressing, activated dendritic cells are disclosed. Such dendritic cells are used to present tumor, viral or bacterial antigens to T cells, and can be useful in vaccination protocols. Other cytokines can be used in separate, sequential or simultaneous combination with the activated, antigen-pulsed dendritic cells. Also disclosed are methods for stimulating an immune response using the antigen-expressing, activated dendritic cells.
    Type: Grant
    Filed: October 29, 1999
    Date of Patent: December 24, 2002
    Assignee: Immunex Corp.
    Inventors: Eugene Maraskovsky, Hilary J. McKenna
  • Interleukin-7
    Patent number: 4965195
    Abstract: Mammalian Interleukin-7 proteins (IL-7s), DNAs and expression vectors encoding mammalian IL-7s, and processes for producing mammalian IL-7s as products of cell culture, including recombinant systems, are disclosed.
    Type: Grant
    Filed: October 7, 1988
    Date of Patent: October 23, 1990
    Assignee: Immunex Corp.
    Inventors: Anthony E. Namen, Raymond G. Goodwin, Stephen D. Lupton, Diane Y. Mochizuki